Miyoung Yoon

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4145026/publications.pdf

Version: 2024-02-01

52 papers	1,404 citations	361296 20 h-index	345118 36 g-index
54 all docs	54 docs citations	54 times ranked	1878 citing authors

#	Article	IF	Citations
1	Considerations for Improving Metabolism Predictions for In Vitro to In Vivo Extrapolation. Frontiers in Toxicology, 2022, 4, 894569.	1.6	10
2	Using quantitative modeling tools to assess pharmacokinetic bias in epidemiological studies showing associations between biomarkers and health outcomes at low exposures. Environmental Research, 2021, 197, 111183.	3.7	9
3	Development and Application of a Life-Stage Physiologically Based Pharmacokinetic (PBPK) Model to the Assessment of Internal Dose of Pyrethroids in Humans. Toxicological Sciences, 2020, 173, 86-99.	1.4	29
4	Quantitative bias analysis of the association between subclinical thyroid disease and two perfluoroalkyl substances in a single study. Environmental Research, 2020, 182, 109017.	3.7	9
5	Population Life-course exposure to health effects model (PLETHEM): An R package for PBPK modeling. Computational Toxicology, 2020, 13, 100115.	1.8	15
6	The role of fit-for-purpose assays within tiered testing approaches: A case study evaluating prioritized estrogen-active compounds in an in vitro human uterotrophic assay. Toxicology and Applied Pharmacology, 2020, 387, 114774.	1.3	10
7	Physiologically Based Pharmacokinetic Modeling in Risk Assessment: Case Study With Pyrethroids. Toxicological Sciences, 2020, 176, 460-469.	1.4	5
8	Physiologically based pharmacokinetic models to support modernized chemical safety assessment. , 2020, , 301-321.		0
9	The TTC Data Mart: An interactive browser for threshold of toxicological concern calculations. Computational Toxicology, 2020, 15, 100128.	1.8	3
10	Application of a combined aggregate exposure pathway and adverse outcome pathway (AEP-AOP) approach to inform a cumulative risk assessment: A case study with phthalates. Toxicology in Vitro, 2020, 66, 104855.	1.1	21
11	Metabolism of deltamethrin and cis- and trans-permethrin by human expressed cytochrome P450 and carboxylesterase enzymes. Xenobiotica, 2019, 49, 521-527.	0.5	17
12	Assessing children's exposure to manganese in drinking water using a PBPK model. Toxicology and Applied Pharmacology, 2019, 380, 114695.	1.3	9
13	Evaluation of Age-Related Pyrethroid Pharmacokinetic Differences in Rats: Physiologically-Based Pharmacokinetic Model Development Using In Vitro Data and In Vitro to In Vivo Extrapolation. Toxicological Sciences, 2019, 169, 365-379.	1.4	19
14	Updating physiologically based pharmacokinetic models for manganese by incorporating rapid association/dissociation processes in tissues. Toxicology and Applied Pharmacology, 2019, 372, 1-10.	1.3	3
15	Incorporation of inÂvitro metabolism data and physiologically based pharmacokinetic modeling in a risk assessment for chloroprene. Inhalation Toxicology, 2019, 31, 468-483.	0.8	12
16	Computational Methods to Predict Toxicity. , 2019, , 287-300.		6
17	Evaluating opportunities for advancing the use of alternative methods in risk assessment through the development of fit-for-purpose in vitro assays. Toxicology in Vitro, 2018, 48, 310-317.	1.1	25
18	Excretion of Di-2-ethylhexyl phthalate (DEHP) metabolites in urine is related to body mass index because of higher energy intake in the overweight and obese. Environment International, 2018, 113, 91-99.	4.8	31

#	Article	IF	Citations
19	Alternative approaches for acute inhalation toxicity testing to address global regulatory and non-regulatory data requirements: An international workshop report. Toxicology in Vitro, 2018, 48, 53-70.	1.1	62
20	An in vitro approach for prioritization and evaluation of chemical effects on glucocorticoid receptor mediated adipogenesis. Toxicology and Applied Pharmacology, 2018, 355, 112-126.	1.3	14
21	Xenobiotic Metabolism in Alginate-Encapsulated Primary Human Hepatocytes Over Long Timeframes. Applied in Vitro Toxicology, 2018, 4, 238-247.	0.6	7
22	Determination of Human Hepatic CYP2C8 and CYP1A2 Age-Dependent Expression to Support Human Health Risk Assessment for Early Ages. Drug Metabolism and Disposition, 2017, 45, 468-475.	1.7	31
23	Quantitative bias analysis of a reported association between perfluoroalkyl substances (PFAS) and endometriosis: The influence of oral contraceptive use. Environment International, 2017, 104, 118-121.	4.8	12
24	Quantitative bias analysis for epidemiological associations of perfluoroalkyl substance serum concentrations and early onset of menopause. Environment International, 2017, 99, 245-254.	4.8	33
25	The application of PBPK models in estimating human brain tissue manganese concentrations. NeuroToxicology, 2017, 58, 226-237.	1.4	26
26	Using exposure prediction tools to link exposure and dosimetry for risk-based decisions: A case study with phthalates. Chemosphere, 2017, 184, 1194-1201.	4.2	22
27	Systems biology for organotypic cell cultures. ALTEX: Alternatives To Animal Experimentation, 2017, 34, 301-310.	0.9	10
28	Fluid Dynamic Modeling to Support the Development of Flow-Based Hepatocyte Culture Systems for Metabolism Studies. Frontiers in Bioengineering and Biotechnology, 2016, 4, 72.	2.0	16
29	Addressing Early Life Sensitivity Using Physiologically Based Pharmacokinetic Modeling and In Vitro to In Vivo Extrapolation. Toxicological Research, 2016, 32, 15-20.	1.1	13
30	Moving Beyond Prioritization Toward True In Vitro Safety Assessment. Applied in Vitro Toxicology, 2016, 2, 67-73.	0.6	5
31	Pharmacokinetic bias analysis of the epidemiological associations between serum polybrominated diphenyl ether (BDE-47) and timing of menarche. Environmental Research, 2016, 150, 541-548.	3.7	15
32	Associations of Perfluoroalkyl Substances (PFAS) with Lower Birth Weight: An Evaluation of Potential Confounding by Glomerular Filtration Rate Using a Physiologically Based Pharmacokinetic Model (PBPK). Environmental Health Perspectives, 2015, 123, 1317-1324.	2.8	164
33	Can the observed association between serum perfluoroalkyl substances and delayed menarche be explained on the basis of puberty-related changes in physiology and pharmacokinetics?. Environment International, 2015, 82, 61-68.	4.8	39
34	A case study on quantitative in vitro to in vivo extrapolation for environmental esters: Methyl-, propyl- and butylparaben. Toxicology, 2015, 332, 67-76.	2.0	23
35	Quantitative in vitro to in vivo extrapolation (QIVIVE): An essential element for in vitro-based risk assessment. Toxicology, 2015, 332, 1-3.	2.0	37
36	Reconstructing exposures from biomarkers using exposure-pharmacokinetic modeling â€“ A case study with carbaryl. Regulatory Toxicology and Pharmacology, 2015, 73, 689-698.	1.3	11

#	Article	IF	Citations
37	Use of in vitro data in developing a physiologically based pharmacokinetic model: Carbaryl as a case study. Toxicology, 2015, 332, 52-66.	2.0	29
38	Systems Pharmacology Modeling. RSC Drug Discovery Series, 2015, , 359-390.	0.2	0
39	Analysis of biomarker utility using a PBPK/PD model for carbaryl. Frontiers in Pharmacology, 2014, 5, 246.	1.6	8
40	Modeling Manganese Kinetics for Human Health Risk Assessment. Issues in Toxicology, 2014, , 322-354.	0.2	0
41	Evaluation of simple in vitro to in vivo extrapolation approaches for environmental compounds. Toxicology in Vitro, 2014, 28, 164-170.	1.1	51
42	Deriving an explicit hepatic clearance equation accounting for plasma protein binding and hepatocellular uptake. Toxicology in Vitro, 2013, 27, 11-15.	1.1	10
43	A Semiphysiologically Based Pharmacokinetic Modeling Approach to Predict the Dose-Exposure Relationship of an Antiparasitic Prodrug/Active Metabolite Pair. Drug Metabolism and Disposition, 2012, 40, 6-17.	1.7	21
44	Application of a Multi-Route Physiologically Based Pharmacokinetic Model for Manganese to Evaluate Dose-Dependent Neurological Effects in Monkeys. Toxicological Sciences, 2012, 129, 432-446.	1.4	23
45	Quantitativein vitrotoin vivoextrapolation of cell-based toxicity assay results. Critical Reviews in Toxicology, 2012, 42, 633-652.	1.9	190
46	Update on a Pharmacokinetic-Centric Alternative Tier II Program for MMTâ€"Part II: Physiologically Based Pharmacokinetic Modeling and Manganese Risk Assessment. Journal of Toxicology, 2012, 2012, 1-17.	1.4	18
47	Use ofin VitroData in PBPK Models: An Example ofin Vitrotoin VivoExtrapolation with Carbaryl. ACS Symposium Series, 2012, , 323-338.	0.5	2
48	Physiologically Based Pharmacokinetic Modeling of Fetal and Neonatal Manganese Exposure in Humans: Describing Manganese Homeostasis during Development. Toxicological Sciences, 2011, 122, 297-316.	1.4	99
49	Analysis of Manganese Tracer Kinetics and Target Tissue Dosimetry in Monkeys and Humans with Multi-Route Physiologically Based Pharmacokinetic Models. Toxicological Sciences, 2011, 120, 481-498.	1.4	59
50	Evaluating Placental Transfer and Tissue Concentrations of Manganese in the Pregnant Rat and Fetuses after Inhalation Exposures with a PBPK Model. Toxicological Sciences, 2009, 112, 44-58.	1.4	76
51	Lactational Transfer of Manganese in Rats: Predicting Manganese Tissue Concentration in the Dam and Pups from Inhalation Exposure with a Pharmacokinetic Model. Toxicological Sciences, 2009, 112, 23-43.	1.4	30
52	Extrahepatic Metabolism by CYP2E1 in PBPK Modeling of Lipophilic Volatile Organic Chemicals: Impacts on Metabolic Parameter Estimation and Prediction of Dose Metrics. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2007, 70, 1527-1541.	1.1	14